Catalyst Pharmaceuticals Stock News

These quiet biotechs are tightly focused and practically alone in their markets.

They've strongly outperformed the market in the past, and they could easily do it again.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)s stock price traded up 2.4% during mid-day trading on Friday . The company traded as high as $6.90 and last traded at $6.88. 2,192 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,217,669 shares. The stock had previously closed at $6.72. Separately, HC [] The post Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 2.4% Higher appeared first on ETF Daily News .

Fisher Asset Management LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 201,801 shares of the biopharmaceutical companys stock, valued at approximately $1,070,000. Fisher Asset Management LLC owned 0.20% of []

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 3,612 shares of the firms stock in a transaction on Tuesday, December 7th. The shares were sold at an average price of $6.99, for a total transaction of $25,247.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Shares []

CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst''s FIRDAPSE ® (amifampridine) 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS").

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY ) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way. Catalysts Bumpy Ride: One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in recent years came in 2018 when the companys Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan in 2019. In early 2020, Catalyst aggressively expanded its sales team to help monetize Firdapse and the company is actively undergoing trials to potentially expand Firdapses label to muscle-specific kinase myasthenia gravis (MuSK-MG) and other indications.

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 1.10% to the previous days close as strong demand from buyers drove the stock to $7.38. Actively observing the price movement in the last trading, the stock closed the session at $7.30, falling within a range of $7.18 The Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Metrics You Need To Know Right Now Read More »

Brokerages expect that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will report earnings of $0.11 per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $0.10 to $0.11. Catalyst Pharmaceuticals also posted earnings of $0.11 per share in the same quarter last year. The firm […]

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)s traded shares stood at 0.59 million during the last session, with the companys beta value hitting 1.33. At the close of trading, the stocks price was $7.32, to imply an increase of 0.27% or $0.02 in intraday trading. The CPRX shares 52-week high remains $7.58, putting it -3.55% down since that What Could Change After Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Gains 56.01% From The High-Point? Read More »

Wall Street analysts expect that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will announce earnings per share (EPS) of $0.11 for the current quarter, according to Zacks. Four analysts have issued estimates for Catalyst Pharmaceuticals earnings. The highest EPS estimate is $0.11 and the lowest is $0.10. Catalyst Pharmaceuticals also posted earnings of $0.11 per share during the []

Goldman Sachs Group Inc. reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 24.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,068,147 shares of the biopharmaceutical companys stock after selling 353,846 shares during the period. Goldman []

Man Group plc trimmed its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 16.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 305,900 shares of the biopharmaceutical companys stock after selling 58,327 shares during the period. Man Group plcs holdings in Catalyst []

Wall Street brokerages predict that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will announce sales of $36.65 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings. The lowest sales estimate is $36.25 million and the highest is $36.85 million. Catalyst Pharmaceuticals reported sales of $31.02 million in the same […]

CORAL GABLES, Fla., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ: CPRX ), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst''s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29, 2021 through December 2, 2021. A webcast of the pre-recorded fireside discussion will be available on the Company''s website when it becomes accessible on the conference portal at 10:00 a.m. ET on Monday, November … Full story available on Benzinga.com